动脉瘤性蛛网膜下腔出血后癫痫风险预测模型:RISE评分
该回顾性纵向研究基于419例动脉瘤性蛛网膜下腔出血(aSAH)患者,开发了预测癫痫风险的RISE评分,并在308例外部验证队列中验证。RISE评分纳入病前改良Rankin量表(mRS)≥2、VASOGRADE评分、手术治疗和早期癫痫发作史,将患者分为低、中、高风险组,5年内癫痫发生率分别为2.9%、20.8%和75.7%,验证队列AUC为0.82(95%CI 0.74-0.90)。
要点
- RISE评分可预测aSAH后5年内癫痫风险,外部验证AUC为0.82(95%CI 0.74-0.90)。
- 低风险(0-1分)、中风险(2-3分)、高风险(4-5分)的癫痫发生率分别为2.9%、20.8%、75.7%。
- 病前mRS≥2、VASOGRADE评分、手术治疗和早期癫痫发作是癫痫的独立相关因素。
核心结论
- RISE评分是aSAH后癫痫的稳健预测工具,具有即刻临床适用性,并可能有助于探索未来的抗癫痫发生策略。
研究设计与样本
- 回顾性纵向研究,纳入2012年至2021年单中心收治的所有成人aSAH患者,最终419例纳入分析;另采用不同三级中心的308例患者进行外部验证。
主要发现
- 中位随访4.2年期间,50例(11.9%)发生癫痫。
- 病前mRS(HR 4.74,95%CI 1.8-12.4,p=0.001)、VASOGRADE评分(HR 2.45,95%CI 1.4-4.2,p=0.001)、手术治疗(HR 2.77,95%CI 1.6-4.9,p=0.001)和早期癫痫发作(HR 1.84,95%CI 1.0-3.4,p=0.05)与癫痫独立相关。
- RISE评分低风险组(0-1分)2.9%发生癫痫,中风险组(2-3分)20.8%发生癫痫,高风险组(4-5分)75.7%发生癫痫。
- 外部验证队列(N=308)中,RISE评分对aSAH后5年内癫痫的预测AUC为0.82(95%CI 0.74-0.90)。
关键数值与推荐
- RISE评分:病前mRS≥2(R)计1分,VASOGRADE-Yellow(I,缺血)计1分,手术治疗(S)计1分,早期癫痫发作史(E)计1分,VASOGRADE-Red计2分。
- 风险分层:低风险0-1分,中风险2-3分,高风险4-5分。
临床怎么用
- RISE评分可帮助对aSAH患者进行癫痫风险分层,优化随访方案并设计预防策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The occurrence of seizures after aneurysmal subarachnoid hemorrhage (aSAH) is associated with a poorer functional and cognitive prognosis and less favorable quality of life. It would be of value to promptly identify patients at risk of epilepsy to optimize follow-up protocols and design preventive strategies. Our aim was to develop a predictive score to help stratify epilepsy risk in patients with aSAH. METHODS: This is a retrospective, longitudinal study of all adults with aSAH admitted to our center (2012-2021). We collected demographic data, clinical and radiologic variables, data on early-onset seizures (EOSs), and data on development of epilepsy. Exclusion criteria were previous structural brain lesion, epilepsy, and ≤7 days' follow-up. Multiple Cox regression was used to evaluate factors independently associated with unprovoked remote seizures (i.e., epilepsy). The best fitting regression model was used to develop a predictive score. Performance was evaluated in an external validation cohort of 308 patients using receiver-operating characteristic curve analysis. RESULTS: From an initial database of 743 patients, 419 met the inclusion criteria and were included in the analysis. The mean age was 60 ± 14 years, 269 patients (64%) were women, and 50 (11.9%) developed epilepsy within a median follow-up of 4.2 years. Premorbid modified Rankin Score (mRS) (hazard ratio [HR] 4.74 [1.8-12.4], p = 0.001), VASOGRADE score (HR 2.45 [1.4-4.2], p = 0.001), surgical treatment (HR 2.77 [1.6-4.9], p = 0.001), and presence of EOSs (HR 1.84 [1.0-3.4], p = 0.05) were independently associated with epilepsy. The proposed scale, designated RISE, scores 1 point for premorbid mRS ≥ 2 (R), VASOGRADE-Yellow (I, Ischemia), surgical intervention (S), and history of EOSs (E) and 2 points for VASOGRADE-Red. RISE stratifies patients into 3 groups: low (0-1), moderate (2-3), and high (4-5) risk (2.9%, 20.8%, and 75.7% developed epilepsy, respectively). On validation in a cohort from a different tertiary care center (N = 308), the new scale yielded a similar risk distribution and good predictive power for epilepsy within 5 years after aSAH (area under the curve [AUC] 0.82; 95% CI 0.74-0.90). DISCUSSION: The RISE scale is a robust predictor of post-SAH epilepsy with immediate clinical applicability. In addition to facilitating personalized diagnosis and treatment, RISE may be of value for exploring future antiepileptogenesis strategies.
引用
- Campos-Fernandez D, Rodrigo-Gisbert M, Abraira L, et al. Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE Score. Neurology. 2024. PMID: 38527232. doi:10.1212/WNL.0000000000209221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。